Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in ContrastASHNCT04700111
Lag of Accommodation With DOT Spectacle Lenses
A study testing DOT Pattern in people with Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast, run by SightGlass Vision, Inc. at 1 site in Canada.
Trial summary
The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles. Read more about this study
- Who is it for?
- Ages 6 to 18 yearsHealthy volunteers can take part
- Conditions the study is for
- Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast
- What is being tested?
- DOT Pattern
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteCanada
- Study dates
- 1 Feb 2022to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 18 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
A person is eligible for inclusion in the study if he/she:
- Age 6-18 years of age, with a maximum of 6 of the first 25 completed participants being older than 14 years of age.
- Is able to read (or be read to), understand and sign the assent document if under 17 years old or is able to read, understand and sign the consent document if aged 17 or 18 years.
- Is under 17 years old and is accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document.
- Should be emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D.
- Is willing and able to follow instructions.
A person will be excluded from the study if he/she:
- Is participating in any concurrent clinical or research study.
- Have a history of myopia control treatment in the past year.
- Has amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency.
- Has any known active ocular disease and/or infection.
- Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism.
- Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops.
- Has undergone strabismus surgery, refractive error surgery or intraocular surgery.
- Is a child of a member of the study team.
Trial locations and contacts
1 site in 1 country.
Canada1 site
Centre for Ocular Research and Education
Waterloo, Ontario, N2L 3G1
About this study
The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.
- Conditions
- Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast
- Being tested
- DOT Pattern, Control Spectacles
- Medical subject headings
- Myopia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DOT PatternDevice
DOT Pattern Spectacle Lens
Control SpectaclesDevice
Control lens
| Study group | Role | What they receive |
|---|---|---|
| Treatment 1 - DOT Pattern | Experimental | Spectacle lens or treatment 1 Receives: Device: DOT Pattern |
| Treatment 2 - Control Spectacles | Active comparator | Comparator lens or control arm Receives: Device: Control Spectacles |
What is being measured
The primary outcome is the main question the study is designed to answer.
Best vision sphere
- Autorefractor spherical equivalent refraction measured at distance and at 40cm with each pair of treatment spectacles
Measured: 90 minutes
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2021
- Study start1 Feb 2022
- Primary completion9 Jun 2022
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in ContrastStudies of the same condition, open and under way.
- More trials run by SightGlass Vision, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- SightGlass Vision, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- University of Waterloo
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04700111
- Sponsor's protocol ID
- CPRO-2011-001
- Acronym
- ASH
- Status last verified
- Apr 2026
- First submitted
- 6 Jan 2021
- Last updated
- 5 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lag of Accommodation With DOT Spectacle Lenses
- ClinicalTrials.gov ID
- NCT04700111
- Acronym / sponsor ID
- ASH / CPRO-2011-001
- Conditions
- Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 30 participants (actual)
- Lead sponsor
- SightGlass Vision, Inc.Industry (pharma, biotech, devices)
- Collaborators
- University of Waterloo
- Study start
- 1 Feb 2022 (actual)
- Primary completion
- 9 Jun 2022 (actual)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 7 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment 1 - DOT Pattern | Experimental | Device: DOT PatternSpectacle lens or treatment 1 |
| Treatment 2 - Control Spectacles | Active comparator | Device: Control SpectaclesComparator lens or control arm |
Who may qualify
- Ages
- 6 to 18 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DOT PatternDOT Pattern Spectacle Lens | Device | Treatment 1 - DOT Pattern |
| Control SpectaclesControl lens | Device | Treatment 2 - Control Spectacles |
Primary outcome
Best vision sphere
Time frame: 90 minutes
1) Autorefractor spherical equivalent refraction measured at distance and at 40cm with each pair of treatment spectacles
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 May 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing DOT Pattern in people with Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast, run by SightGlass Vision, Inc. at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Best vision sphere (time frame: 90 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.